ClinicalTrials.gg
Active, not recruitingNCT04732845Updated Sep 23, 2026

Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

A Phase 1 interventional study of Fully human anti CD19 CAR-T Cell Dose and Fludarabine in Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia, sponsored by Benjamin Tomlinson. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Benjamin Tomlinson · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States — 137 open to participants now, 253 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Enrollment
984th of 1,378
18 · median 35
Started
2021
with 53 others
Phase 1
529 of 1,600
48 open now
Primary completion
2025-12
later than 52 of 248 live
Registered
1,385th of 1,600
by date

Among the 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is the 984th largest by enrollment of the 1,378 interventional ones that give a count, is one of 54 that started in 2021, is one of 529 in phase 1, reaches primary completion later than 52 of the 248 other live ones, and was the 1,385th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

137 of the 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,600 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based immunotherapy (therapy that uses the immune system to treat the cancer).

Read the detailed description

This study seeks to determine the safety of the treatment of relapsed or refractory B cell lymphomas, relapsed/ refractory chronic lymphocytic leukemia and relapsed/refractory acute lymphoblastic leukemia with chimeric antigen receptor T cells targeting CD19 and to find the recommended phase II dose for this cellular therapy.

T cells are a type of white blood cell that helps the body fight infections. This treatment uses T cells already present within the body that have been modified outside of the body by a lentivirus and then returned to the participant by an infusion to target the cancer. Lentivirus is a family of viruses that can be used by scientists to alter cells, which then could be used to change the course of a disease. This type of treatment is sometimes referred to as adoptive cell transfer (ACT). In this study the specific type of cells that will be used is called human chimeric antigen receptor T cells (CAR-T cells). The CAR-T cells that will be reinfused to the body are modified using a lentivirus that is no longer active. The CAR-T cells will be returned to the body through an intravenous (IV) infusion. Another purpose of this study is to learn about the side effects and toxicities related to this treatment. Human CAR-T cell therapy is investigational (experimental) and works by removing T cells from the blood and modifying them to be able to target the cancer.

03

Conditions studied

  • Non Hodgkin Lymphoma
  • Acute Lymphoblastic Leukemia
  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have non-Hodgkin lymphoma (NHL) (Group A - NHL/CLL), chronic lymphocytic leukemia (Group A - NHL/CLL) or acute lymphoblastic leukemia (Group B - ALL) treated with at least two . Disease must have either progressed after the last regimen or presented failure to achieve complete remission with the last regimen.
  • The participant's is CD19 positive, either by immunohistochemistry or flow cytometry analysis on the last available or peripheral blood for circulating disease.
  • (ECOG) Performance status ≤ 2
  • Total ≤ 1.5 times the institutional unless bilirubin rise is due to Gilbert's syndrome (maximum 2 time normal) or of non-hepatic origin
  • (SGOT) ≤ 3 times institutional upper limit of normal
  • ALT (SGPT) ≤ 3 times institutional upper limit of normal
  • Serum Creatinine ≤ 2 times the institutional upper limit of normal and ≥ 30 mL/min (calculated or measured)
  • Must have adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air.
  • Must have adequate cardiac function as defined as ≥ 40% in the most recent echocardiogram.
  • Absolute Lymphocyte Count >100/microliter (uL)
  • Participants (or legal guardians) must have the ability to understand and the willingness to sign a written document.
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use a method with a failure rate of \< 1% per year during the treatment period and for at least 90 days after the human anti-CD19 CAR-T cell infusion. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a state (\< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for at least 6 months after the human anti-CD19 CAR-T cell infusion. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the human antiCD19 CAR-T cell infusion to avoid potential embryonal or fetal exposure. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods

Exclusion criteria

Exclusion Criteria:

  • transplant within 6 weeks of planned CAR-T cell infusion.
  • Allogeneic stem cell transplant within 3 months of planned CAR-T cell infusion and patients must be off agents.
  • Active .
  • Active central nervous system or meningeal involvement by lymphoma or leukemia. Subjects with untreated /central nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • Participants with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced MRI imaging for at least 90 days prior to registration.
  • Second active , other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast).
  • A minimum of 28 days must have elapsed between prior treatment with agent(s) and the day of lymphocyte collection.
  • seropositivity.
  • Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of must have a negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.
  • Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on screening bone marrow prior
  • Serologic status reflecting active or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
  • Participants with history of CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.
  • History of disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Group A - NHL/CLL

    Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done. Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m\^2 Fludarabine from day -5 to day -3. Participants with CD19+ lymphomas and chronic lymphocytic leukemia will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at dose level 1 (DL1) on day 0. The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD.

    Biological: Fully human anti CD19 CAR-T Cell Dose · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Group B - ALL

    Upon enrollment, peripheral blood mononuclear cells will be collected, and T-cell selection and manufacture of CAR-T cells will be done. Participants will receive 60 mg/Kg/IV Cyclophosphamide on day -6 and 25 mg/m\^2 Fludarabine from day -5 to day -3. Participants with Acute Lymphoblastic Leukemia (and lymphoblastic lymphoma as a solid tumor equivalent) will be enrolled on this arm sequentially in a 3 + 3 design starting with infusion of CAR-T cells at DL1 on day 0 and 7. The maximum tolerated dose (MTD) will be determined and then 6 additional participants will be enrolled at the MTD.

    Biological: Fully human anti CD19 CAR-T Cell Dose · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • BiologicalFully human anti CD19 CAR-T Cell Dose

    Level -1 (1 x 10\^5 cells/kg) Level 1 \[Starting Dose\] (5 x 10\^5 cells/kg) Level 2 (1 x 10\^6 cells/kg) Level 3 (2 x 10\^6 cells/kg) Infusion of CAR-T cells will occur over 5-30 minutes.

  • 25 mg/m2 daily from day -5 to -3

    Also known as: Fludara

  • 60mg/Kg on day -6

    Also known as: Cytoxan, Endoxan, Neosar, Procytox, Revimmune, Cycloblastin

06

What researchers measure

Primary outcomes

  1. Recommended phase II dose of human anti-CD19 CAR-T cells

    Recommended phase II dose of human anti-CD19 CAR-T cells

    Time frame: 24 months

Secondary outcomes

  1. Number of participants experiencing grade 3 or more adverse events

    Toxicity profile for to infusion of fully human CAR-T cells, as measured by number of participants experiencing grade 3 or more adverse events

    Time frame: 18 months

  2. Number of participants experiencing dose limiting toxicities

    Toxicity profile for to infusion of fully human CAR-T cells, as measured by number of participants experiencing dose limiting toxicities

    Time frame: 18 months

  3. Overall response rate (ORR)

    ORR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 30 days after day 0 (first CAR-T treatment)

  4. Overall response rate (ORR)

    ORR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 60 days after day 0 (first CAR-T treatment)

  5. Overall response rate (ORR)

    ORR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 90 days after day 0 (first CAR-T treatment)

  6. Overall response rate (ORR)

    ORR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 6 months after day 0 (first CAR-T treatment)

  7. Overall response rate (ORR)

    ORR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 12 months after day 0 (first CAR-T treatment)

  8. Complete response rate (CR)

    CR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 30 days after day 0 (first CAR-T treatment)

  9. Complete response rate (CR)

    CR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 60 days after day 0 (first CAR-T treatment)

  10. Complete response rate (CR)

    CR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 90 days after day 0 (first CAR-T treatment)

  11. Complete response rate (CR)

    CR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 6 months after day 0 (first CAR-T treatment)

  12. Complete response rate (CR)

    CR relapsed B cell malignancies treated with CAR-T cells targeting CD19

    Time frame: 12 months after day 0 (first CAR-T treatment)

  13. Progression Free Survival (PFS)

    PFS from time of infusion

    Time frame: 30 days after day 0 (first CAR-T treatment)

  14. Progression Free Survival (PFS)

    PFS from time of infusion

    Time frame: 60 days after day 0 (first CAR-T treatment)

  15. Progression Free Survival (PFS)

    PFS from time of infusion

    Time frame: 90 days after day 0 (first CAR-T treatment)

  16. Progression Free Survival (PFS)

    PFS from time of infusion

    Time frame: 6 months after day 0 (first CAR-T treatment)

  17. Progression Free Survival (PFS)

    PFS from time of infusion

    Time frame: 12 months after day 0 (first CAR-T treatment)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie or influence the results observed from the study

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Beginning 3 months and ending 5 years following article publication

Access criteria: Link to be provided at time of article publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Dec 2025, 55 months.

Of 123 non-industry phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 80. This study's 55 months is close to that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2021
First posted
Feb 1, 2021
StartActual
Apr 26, 2021
Primary completionActual
Dec 11, 2025
CompletionEst.
Dec 1, 2040
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04732845
Lead sponsor
Benjamin Tomlinson
Responsible party
Benjamin Tomlinson (Principal Investigator, Case Comprehensive Cancer Center) — Sponsor-investigator
First posted
Feb 1, 2021
Start date
Apr 26, 2021
Primary completion
Dec 11, 2025
Completion
Dec 1, 2040 (estimated)
Last update
Sep 23, 2026

Study contacts

Benjamin Tomlinson, MD
principal investigator · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion